ESTRO 2024 - Abstract Book

S1064

Clinical - Gynaecology

ESTRO 2024

Conclusion:

Our retrospective analysis identified age, MMI, and ER status as significant prognostic factors for recurrence in early-stage endometrial cancer. Patients over 70 years of age or those with ER-negative tumors should be considered for intensive adjuvant therapy if available. Molecular subtype did not demonstrate prognostic value. Future studies should aim to validate and assess the significance of integrating novel markers. 

Keywords: Endometrial cancer, Pattern of recurrence

2182

Digital Poster

Neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.

Vinay Babu Venkataramana 1 , Vivek Anand 1 , Ranjeet Bajpai 2 , Simon Paul 1 , Ritika Hinduja 1 , Manish Bhadane 1 , Sudesh Deshpande 1 , Suresh Naidu 1 , Asha Kapadia 3 , Sachin Almel 3 , Murad Lala 4 , Kannan Venkatesan 1 1 P D Hinduja Hospital, Radiation Oncology, Mumbai, India. 2 H N Reliance Hospital, Radiation Oncology, Mumbai, India. 3 P D Hinduja Hospital, Medical Oncology, Mumbai, India. 4 P D Hinduja Hospital, Surgical Oncology, Mumbai, India

Purpose/Objective:

Carcinoma cervix is the fourth most common malignancy and the fourth leading cause of death in females worldwide 1 . Currently, platinum based concurrent chemoradiotherapy (CCRT) is the gold standard for locally advanced cervical carcinoma (LACC). However, the overall survival (OS) for stage IIB and III-IV cancer is approximately 60–65% and 25%-50%, respectively, which are considerably low 2 . Therefore, developing new treatment strategies to improve survival is imperative. This study is aimed to evaluate the effect of neoadjuvant chemotherapy (NACT) for locally advanced cervical cancers.

Material/Methods:

We reviewed 36 patients with International Federation of Gynaecology and Obstetrics (FIGO) 2018 stage III-IVB cervical carcinoma who received NACT prior to standard pelvic chemoradiotherapy, between January 2015 to June 2022. The primary endpoints were 4-year OS (overall survival), PFS (progression-free survival) and DMFS (distant